About Mylan Laboratories Limited
Data last updated: 17 December 2025
Mylan Laboratories Limited is a public limited company based in Hyderabad, Telangana, India, a subsidiary of Mp Laboratories (Mauritius) Ltd. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 29 November 1984, the company has been in operation for over 42 years.
Registered with ROC Hyderabad under CIN U24231AP1984PLC005146.
Capital: an authorised share capital of ₹125 Cr and a paid-up capital of ₹48.7 Cr. Formerly known as Herren Drugs P Ltd and Matrix Laboratories Limitted. It is led by directors including Rajiv Malik and Akshay Nanda.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Plot No.564/A/22 Road No.92 Jubilee Hills, Hyderabad, Telangana, India – 500096.
As per the financials filed for FY 2025, the company reported a revenue of ₹7,503.56 Cr, a decline of 23% compared to the previous year.
The company has a workforce of approximately 11,193 employees as per the latest available data. It operates as a subsidiary of Mp Laboratories (Mauritius) Ltd.
The company is associated with 1 brand - Viatris. As per MCA filings, the company has satisfied charges of ₹5,501.38 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website viatris.com.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media
-
Registered AddressPlot No.564/A/22 Road No.92 Jubilee Hills, Hyderabad, Telangana, India – 500096
-
IndustryPharma, API Manufacturers, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Mylan Laboratories Limited
Mylan Laboratories Limited has undergone 4 name changes throughout its history. The current legal name is Mylan Laboratories Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Mylan Laboratories Limited | Current |
| Herren Drugs P Ltd | Previous |
| Matrix Laboratories Limitted | Previous |
| Herren Drugs Ltd | Previous |
| Herren Drugs & Pharmaceuticals Ltd | Previous |
CIN History of Mylan Laboratories Limited
Mylan Laboratories Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U24231TG1984PLC005146, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24231TG1984PLC005146 | Current |
| U24231AP1984PLC005146 | Previous |
| L24231AP1984PLC005146 | Previous |
Associated Brands with Mylan Laboratories Limited
Mylan Laboratories Limited operates one associated brand: Viatris. These brands represent Mylan Laboratories Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Branded pharmaceuticals are developed and commercialized by Viatris internationally. | viatris.com |
Business Activity of Mylan Laboratories Limited
Mylan Laboratories Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Board of Directors of Mylan Laboratories Limited
Mylan Laboratories Limited is currently managed by 7 directors, with 22 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rajiv Malik | Director | 28 Jul 2005 | 20 Years 11 Months | Current |
| Akshay Nanda | Director | 01 Mar 2024 | 2 Years 4 Months | Current |
| Arvind Shankar Kanda | Whole-Time Director | 28 Mar 2024 | 2 Years 3 Months | Current |
| Ramya Suresh | Director | 25 Apr 2024 | 2 Years 2 Months | Current |
| Sarada Kalyani Bhagawati | Whole-Time Director | 01 Nov 2014 | 11 Years 8 Months | Current |
|
Nagaraj Goud Bodige
Also directs:
Famy Life Sciences Private Limited
|
Nodal Officer | 22 Nov 2022 | 3 Years 7 Months | Current |
Financials of Mylan Laboratories Limited FY 2025 filings available
Mylan Laboratories Limited reported revenue of ₹7,503.56 Cr (down 23% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Charges & Borrowings of Mylan Laboratories Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Jun 2013 | Icici Bank Limited | ₹170 Cr | Satisfied |
| 27 Nov 2012 | Yes Bank Limited | ₹40 Cr | Satisfied |
| 08 Oct 2012 | Export - Import Bank of India | ₹150 Cr | Satisfied |
| 18 Jul 2012 | The Ratnakar Bank Limited | ₹50 Cr | Satisfied |
| 10 Jul 2012 | Yes Bank Limited | ₹60 Cr | Satisfied |
Total charge records: 55 View all charges
Employees and EPFO Compliance at Mylan Laboratories Limited
View historical data on people associated with Mylan Laboratories Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Mylan Laboratories Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Mylan Laboratories Limited
GSTIN & GST Filing Data of Mylan Laboratories Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Mylan Laboratories Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Mylan Laboratories Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Mylan Laboratories Limited
MSME Payment Delays by Mylan Laboratories Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Mylan Laboratories Limited
Subsidiaries & Group Companies of Mylan Laboratories Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Mylan Laboratories Limited with ownership details.
MCA Filings & Documents of Mylan Laboratories Limited
MCA Filings & Documents of Mylan Laboratories Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Mylan Laboratories Limited
Recent News on Mylan Laboratories Limited
Frequently Asked Questions about Mylan Laboratories Limited
Mylan Laboratories Limited is an active public limited company in the pharma sector based in Hyderabad, Telangana, India. It was incorporated on 29 November 1984 (42+ years old) and is registered under CIN U24231TG1984PLC005146. The company has 11,193 employees.
Mylan Laboratories Limited reported revenue of ₹7,503.56 Cr for FY 2025 (down 23.00% YoY).
The current directors of Mylan Laboratories Limited are:
- Rajiv Malik
- Akshay Nanda
- Arvind Shankar Kanda
- Ramya Suresh
- Sarada Kalyani Bhagawati
- Nagaraj Goud Bodige
- Nagaraj Goud Bodige
The primary industry of Mylan Laboratories Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Mylan Laboratories Limited can be reached at the registered office: Plot No.564A22 Road No.92 Jubilee Hills, Hyderabad, Telangana, India – 500096, or through the website viatris.com.
The authorised capital is ₹125 Cr, and the paid-up capital is ₹48.7 Cr.